60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2).
EO2463 plus R2 was well tolerated in patients with...

The Company, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with...

Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing.

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, will present positive data from its Phase 1/2 clinical study with...

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces it will present new positive data from its ongoing...

Breakthrough study published in Frontiers in Immunology demonstrates CIT-013’s effectiveness against additional types of extracellular traps, expanding potential therapeutic...

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Cmbio™, a global leader in multi-omics science and digital biology, announces a strategic partnership with Nimble Science, to deliver first in class high-quality, multi-omic...

Cmbio®, a global leader in multi-omics science and digital biology, is pleased to announce the purchase of the e[datascientist]™ software platform through an Asset Sale...